EYPT Q4 2020 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-17.4% YoY

Gross Profit

$5M65.5% margin

Operating Income

-$13M-178.6% margin

Net Income

-$15M-216.9% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

-54.6%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$92M

Total Liabilities

$73M

Stockholders' Equity

$19M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$9M	-17.4%
Gross Profit	$5M	$7M	-36.1%
Operating Income	-$13M	-$9M	-41.8%
Net Income	-$15M	-$10M	-48.6%

Revenue Segments

Product

$7M50%

Y U T I Q Product

$4M30%

D E X Y C U Product

$3M20%